Background: Circadian rhythm dysregulation may contribute to sleep-wake disorders and cognitive impairment. In the elderly, circadian abnormalities have been observed in Mild Cognitive Impairment (MCI), suggesting a possible association between neurocognitive deficits and circadian dysfunctions. Objective: To analyze the association between circadian rhythm disturbances and cognitive decline in the population aged ≥ 60 years. Methods: This systematic review included studies evaluating the association between circadian rhythm disturbances and cognitive decline in elderly individuals aged 60 years or older, with self-reported or objectively measured sleep data and cognitive assessment via questionnaires. Studies tracking progression from MCI to Alzheimer’s disease (AD) were retained, as they capture circadian changes across the MCI-to-dementia continuum. Studies that evaluated other sleep disorders and/or other conditions of cognitive impairment exclusively or that did not specify the mean age of the participants were excluded. Results: Ten studies were included, totaling 5,731 participants (5 , 707 eligible for analysis ). Circadian exposures were organized into three domains: (1) actigraphic rest-activity rhythm metrics (amplitude, robustness, interdaily stability, intradaily variability, and acrophase); (2) sleep quality and architecture parameters (efficiency, fragmentation, latency, WASO, and melatonin timing); and (3) circadian-disrupting lifestyle exposures (rotating night shift work). Across these domains, circadian dysregulation was consistently associated with a higher risk of development or progression of MCI and dementia. Conclusion: Circadian and sleep disturbances negatively impact cognitive health in the elderly, reinforcing the need for further research on this association and its public health implications.
20 August 2026 in Headache: The Journal of Head and Face Pain
Post-stroke fatigue (PSF) is a common and disabling condition that limits rehabilitation and quality of life, yet no pharmacological treatment is well established. Modafinil, a wakefulness-promoting agent, has been proposed as a potential therapy. This systematic review and meta-analysis evaluated its efficacy and safety in PSF. Four studies (two RCTs, two observational) comprising 1001 met inclusion criteria. Modafinil did not significantly improve overall fatigue severity on the MFI or FSS. A domain-specific benefit was observed for mental fatigue (MD -2.51; p = 0.0005), with no significant effects on physical, general, or activity-related fatigue. No improvements were found in quality of life (SSQoL) or cognition (MoCA). Modafinil was generally well tolerated with few mild adverse events. Current evidence does not support modafinil as a routine treatment for PSF. Its effect on mental fatigue is of very low certainty, limiting the strength of this finding. Clinicians should interpret these findings cautiously, and use modafinil only on a case-by-case basis. Larger, high-quality trials with standardized fatigue measures are needed to identify responders and clarify its clinical role.
17 August 2026 in Otolaryngology–Head and Neck Surgery
Wea im to evaluate the impact of Dual Antiplatelet Therapy (DAPT) pretreatment on outcomes in patients with Acute Ischemic Stroke (AIS) undergoing intravenous thrombolysis (IVT). A systematic search was conducted from inception to January 2025. Eligible studies included randomized and observational cohorts comparing AIS patients with and without DAPT pretreatment who underwent IVT. Primary outcome was favorable functional outcome at 90 days (mRS 0-1). Secondary outcomes included mRS 0-2, mRS 3-6, in-hospital and 90-day mortality, and symptomatic intracranial hemorrhage (sICH) defined by SITS-MOST, ECASS II, and NINDS criteria. Risk of bias was assessed using the ROBINS-I tool, and meta-analyses were performed with random-effects models. Eight studies including 296,854 patients (61,925 with DAPT and 234,929 without DAPT) were analyzed. DAPT pretreatment was not associated with favorable functional outcome (mRS 0-1; OR: 1.03; 95% CI: 0.92-1.16; p = 0.57; I2 = 0%), in-hospital mortality (OR: 1.00; 95% CI: 1.00-1.00; I2 = 0%), or 90-day mortality (OR: 1.49; 95% CI: 0.99-2.25; p = 0.06; I2 = 52%). No significant increase in sICH was observed using SITS-MOST (I2 = 64%) or ECASS II (I2 = 63%), whereas sICH defined by NINDS was increased (OR: 1.31; 95% CI: 1.19-1.44; p < 0.01; I2 = 48%), corresponding to a 1% absolute risk increase (RD: 0.01; I2 = 0%). Prestroke DAPT was not associated with favorable functional outcome or reduced mortality after IVT and was associated with a higher risk of sICH when defined by NINDS criteria, with a 1% absolute risk increase.